Depression

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

Case reports have shown a potential association with adverse psychological effects.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The CBT-based intervention, compared with routine pregnancy care, demonstrated reductions of 81% and 74% for depression and anxiety, respectively.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

One significant difference was an increased rate of bupropion prescriptions for transgender females.

Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

Investigators determined the effectiveness of behavioral activation psychotherapy versus antidepressant medication management for inpatients with heart failure and depression.

As the body of data has grown, clinicians’ propensity to use selective serotonin reuptake inhibitors off-label has increased

Gepirone does not induce sexual dysfunction, a common limitation associated with SSRIs.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Pharmacists are accessible and trusted health care professionals who have an important role in supporting people living with mental illness.

Modern society has put individuals at an increased risk of dopamine overload, causing an increase in mental health disorders.